SCHEMBL839637

SCHEMBL839637

CCOC(=O)C(CCc1ccccc1)Sc1ncnc2c1cnn2-c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 11/20 0.56
MAPT P10636 7/20 0.51
ALDH1A1 P00352 6/20 0.51
LMNA P02545 3/20 0.51
MAPK1 P28482 2/20 0.51
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 1/20 0.48
RAB9A P51151 2/20 0.47
S1PR2 O95136 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KCNH2 Q12809 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18236417 0.77 ALDH1A1 (0.72) MAPTALDH1A1LMNAMAPK1TSHR
SCHEMBL839071 0.73 ALDH1A1 (0.52) GCKMAPTALDH1A1LMNAMAPK1
SCHEMBL838152 0.72 GCK (0.72) GCKKCNH2
SCHEMBL838958 0.72 GCK (0.68) GCKMAPTALDH1A1MAPK1SMN1; SMN2
SCHEMBL18236415 0.72 MAPT (0.70) MAPTALDH1A1LMNAMAPK1TSHR
SCHEMBL837765 0.72 GCK (1.00) GCKMAPTALDH1A1LMNAMAPK1
SCHEMBL837764 0.72 GCK (1.00) GCKMAPTALDH1A1LMNAMAPK1
SCHEMBL838250 0.72 GCK (1.00) GCKMAPTALDH1A1LMNAMAPK1
SCHEMBL838702 0.71 GCK (1.00) GCKMAPTALDH1A1LMNAMAPK1
SCHEMBL837953 0.71 GCK (0.69) GCKMAPTALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 GCK 1/4885MAPT 3944/4885ALDH1A1 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.